一种工程 IL-2 部分激动剂促进 CD8+ T 干细胞
1Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Nature
|September 16, 2021
概括
一种工程化细胞因子H9T扩大CD8+T细胞用于癌症免疫疗法,而不会导致终端分化. 这种方法保持了类似干细胞的状态,在临床前模型中增强了抗瘤活性.
科学领域:
- 免疫学
- 分子生物学
- 生物技术
背景情况:
- 采用T细胞转移是一种关键的癌症免疫治疗策略.
- T细胞数量和分化状态对治疗疗效产生重大影响.
- 标准的T细胞扩张方法可能导致终端分化和有效性降低.
研究的目的:
- 为了研究H9T的作用,一个工程介素-2部分激动剂,在CD8+T细胞扩张和分化.
- 确定H9T是否可以在T细胞中保持类似干细胞的状态以改善免疫疗法.
- 在临床前癌症模型中评估H9T扩增T细胞的治疗潜力.
主要方法:
- 使用H9T,一种工程性互白素-2部分激动剂,用于T细胞扩张.
- 分析了STAT5信号,转录,表观遗传和代谢变化.
- 评估T细胞转录因子1 (TCF-1) 表达和线粒体适应性.
- 在小鼠模型中评估H9T扩增T细胞的抗瘤活性.
主要成果:
- H9T促进了CD8+T细胞的扩张,而没有导致终端分化.
- 观察到不同的下游转录,表观遗传和代谢程序.
- H9T维持了TCF-1的表达,并促进了线粒体的适应性,保持了类似干细胞的状态.
- 在体内,H9T扩展的TCR转基因和CAR修饰的T细胞表现出强大的抗瘤活性.
结论:
- 像H9T这样的工程细胞因子变异为增强T细胞基础癌症免疫疗法提供了有前途的策略.
- H9T促进了功能性,类似干细胞的CD8+T细胞的扩张.
- 这种方法具有开发新型免疫治疗剂的翻译潜力.
相关概念视频
Cells of the Adaptive Immune Response
6.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.9K
T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
Cytotoxic T Cells-mediated Immune Response
7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


